doxorubicin and epirubicin exhibited a superior response rate in previously untreated patients [ six of eight ( 75 % ) vs eight of 11 ( 73 % ) ] compared to those previously given cmf with or without endocrine therapy [ five of 13 ( 38 % ) vs five of ten ( 50 % ) ] .
C0013089
doxorubicin
C0014582
epirubicin